

Most Read This Week
Recently Updated
- Longer Term Outcomes With Pembrolizumab Plus Axitinib for Advanced RCC
- Peri-Operative Morbidity and Mortality Among Patients Undergoing Cytoreductive Nephrectomy
- Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic
- Immune Checkpoint Inhibitors + Tyrosine Kinase Inhibitors for the Treatment of RCC
- Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell RCC